Hyderabad: Hyderabad-based Dr. Reddy’s Laboratories Ltd on Thursday announced the launch of its anti-cancer drug Toripalimab in the Country. The drug is the only immuno-oncology drug approved by ...

Branded Markets (India and Emerging Markets), Dr. Reddy’s said in a release. It is the `only immuno-oncology drug approved by various regulatory authorities around the world such as the United ...

New Delhi, Nov 28 (PTI) Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal ...

Dr. Reddy’s Laboratories Ltd ... It is the only immuno-oncology drug approved by multiple regulatory authorities worldwide, including the United States Food and Drug Administration (USFDA ...

Over a thousand students and dozens of educators offered ideas for how to have meaningful discussions about difficult topics. Here are some practical ideas — for use in or out of school. By ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare ...

After hours: November 29 at 4:55 PM EST ...

Only immuno-oncology drug approved by various regulatory authorities ... to receive access to this New Biological Entity (NBE) Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE ...

Dr Reddy’s Laboratories on November 28 launched India's first immuno-oncology drug, Toripalimab, to treat a rare form of cancer. The drug is approved for the treatment of nasopharyngeal ...

At the start, none of them had noticeable memory or thinking problems. Researchers asked participants about their use of anticholinergic drugs—whether they had taken them weekly for more than ...

Neutral Dr Reddys Laboratories; target of Rs 1390: Motilal Oswal Nov 06 2024 08:21 PM Hold Dr Reddyu2019s Laboratories; target of Rs 1270: ICICI Securities Nov 06 2024 01:35 PM Sell Dr Reddy's ...